Antibody pharmacokinetics and pharmacodynamics

Journal of Pharmaceutical Sciences

Volumn 93, Issue 11, 2004, Pages 2645-2668

  Lobo, Evelyn D ^a   Hansen, Ryan J ^a   Balthasar, Joseph P ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; BASILIXIMAB; CETUXIMAB; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; HEPATITIS B ANTIBODY; HERPES ZOSTER IMMUNOGLOBULIN; HYBRID PROTEIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLIXIMAB; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OKT 3; OMALIZUMAB; PALIVIZUMAB; RABIES IMMUNOGLOBULIN; RHESUS D ANTIBODY; RITUXIMAB; TETANUS ANTIBODY; THYMOCYTE ANTIBODY; TOSITUMOMAB; TRASTUZUMAB; UNINDEXED DRUG;

ANTIBODY RESPONSE; ANTIGEN BINDING; CATABOLISM; CELL FUNCTION; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; HUMAN; PASSIVE IMMUNIZATION; SHORT SURVEY;

EID: 8644234910     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20178     Document Type: Short Survey

References (147)

1. Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW, Jr., Peck CC. 2001. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: A conference report. Clin Pharmacol Ther 69:387-399.
2. Frazer JK, Capra JD. 1999. Immunoglobulins: Structure and function. In: Fundamental immunology, 4th edn, Philadelphia: Lippincott-Raven, pp 37-74.
3. Mountain A, Adair JR. 1992. Engineering antibodies for therapy. Biotechnol Genet Eng Rev 10: 1-142.
4. Klingbeil C, Hsu DH. 1999. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Toxicol Pathol 27:1-3.
5. Rebello PR, Hale G, Friend PJ, Cobbold SP, Waldmann H. 1999. Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 68:1417-1420.
6. Losonsky GA, Johnson JP, Winkelstein JA, Yolken RH. 1985. Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J Clin Invest 76:2362-2367.
7. Blum PM, Phelps DL, Ank BJ, Krantman HJ, Stiehm ER. 1981. Survival of oral human immune serum globulin in the gastrointestinal tract of low birth weight infants. Pediatr Res 15:1256-1260.
8. Guarino A, Canani RB, Russo S, Albano F, Canani MB, Ruggeri FM, Donelli G, Rubino A. 1994. Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. Pediatrics 93:12-16.
9. Junghans RP. 1997. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 16:29-57.
10. Waldmann TA, Jones EA. 1972. The role of cell-surface receptors in the transport and catabolism of immunoglobulins. Ciba Found Symp 9:5-23.
11. Simister NE, Mostov KE. 1989. Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog. Cold Spring Harb Symp Quant Biol 54(Pt 1):571-580.
12. Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, Wang Y, Robert C, Wu B, Smith PD, Lencer WI, Blumberg RS. 2001. MHC class I-related neonatal Fc receptor for IgG is functionally ex pressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol 166:3266-3276.
13. Aarli A, Matre R, Thunold S. 1991. IgG Fc receptors on epithelial cells of distal tubuli and on endothelial cells in human kidney. Int Arch Allergy Appl Immunol 95:64-69.
14. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, Lencer WI. 2002. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: Functional expression of FcRn in the mammalian lung. J Exp Med 196:303-310.
15. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, Hart TK, Hottenstein CS, Tobia LA, Davis CB. 1999. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 291:1060-1067.
16. Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M, Rhodes GR. 1995. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos 23:1028-1036.
17. Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. 2000. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 34:161-164.
18. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB. 1999. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378.
19. Pepin S, Lutsch C, Grandgeorge M, Scherrmann JM. 1995. Snake F(ab′)2 antivenom from hyperimmunized horse: Pharmacokinetics following intravenous and intramuscular administrations in rabbits. Pharm Res 12:1470-1473.
20. Lebsack ME, Hanna RK, Lange MA, Newman A, Ji W, Korth-Bradley JM. 1997. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers. Pharmacotherapy 17:1118-1119.
21. Vaishnaw AK, TenHoor CN. 2002. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 29:415-426.
22. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. 1986. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res 46:3969-3978.
23. Baxter LT, Zhu H, Mackensen DG, Jain RK 1994. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54: 1517-1528.
24. Flessner MF, Lofthouse J, Zakaria el R. 1997. In vivo diffusion of immunoglobulin G in muscle: Effects of binding, solute exclusion, and lymphatic removal. Am J Physiol 273:H2783-H2793.
25. Bill A. 1977. Plasma protein dynamics: Albumin and IgG capillary permeability, extravascular movement, and regional blood flow in unanesthetized rabbits. Acta Physiol Scand 101:28-42.
26. Juweid M, Strauss HW, Yaoita H, Rubin RH, Fischman AJ. 1992. Accumulation of immunoglobulin G at focal sites of inflammation. Eur J Nucl Med 19:159-165.
27. Hedger MP, Hettiarachchi S. 1994. Measurement of immunoglobulin G levels in adult rat testicular interstitial fluid and serum. J Androl 15:583-590.
28. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS, Lencer WI. 1999. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104:903-911.
29. McCarthy KM, Yoong Y, Simister NE. 2000. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: A system to study protein transport across epithelia. J Cell Sci 113:1277-1285.
30. Antohe F, Radulescu L, Gafencu A, Ghetie V, Simionescu M. 2001. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol 62:93-105.
31. Gibaldi M, Perrier D. 1982. Pharmacokinetics. In: Swarbrick J, editor. Drugs and the pharmaceutical sciences, Vol. 15. New York: Marcel Dekker, 494p.
32. Molthoff CF, Pinedo HM, Schluper HM, Nijman HW, Boven E. 1992. Comparison of the pharmacokinetics, biodistribution, and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab′)2 fragments in experimental ovarian cancer. Br J Cancer 65:677-683.
33. Kairemo KJ, Lappalainen AK, Kaapa E, Laitinen OM, Hyytinen T, Karonen SL, Gronblad M. 2001. In vivo detection of intervertebral disk injury using a radiolabeled monoclonal antibody against keratan sulfate. J Nucl Med 42:476-482.
34. Danilov SM, Gavrilyuk VD, Franke FE, Pauls K, Harshaw DW, McDonald TD, Miletich DJ, Muzykantov VR. 2001. Lung uptake of antibodies to endothelial antigens: Key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 280:L1335-L1347.
35. Delacroix DL, Hodgson HJ, McPherson A, Dive C, Vaerman JP. 1982. Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immunoglobulin M, and other proteins in serum, bile, and saliva. J Clin Invest 70:230-241.
36. Waldmann TA, Strober W. 1969. Metabolism of immunoglobulins. Prog Allergy 13:1-110.
37. Brambell FWR, Hemmings WA, Morris IG. 1964. A theoretical model of gamma-globulin catabolism. Nature 203:1352-1355.
38. Junghans RP, Anderson CL. 1996. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93:5512-5516.
39. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. 1996. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26:690-696.
40. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. 1996. Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn. Immunology 89:573-578.
41. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES. 1997. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 15:637-640.
42. Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. 2002. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences. J Immunol 169:5171-5180.
43. Imbach P, d'Apuzzo V, Hirt A, Rossi E, Vest M, Barandum S, Baumgartner C, Morell A, Schomi M, Wagner HP. 1981. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1228-1231.
44. Emmi L, Chiarini F. 2002. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci 23(Suppl 1): S1-S8.
45. Hansen RJ, Balthasar JP. 2001. Pharmacokinetics, pharmacodynamics, and platelet binding of 7E3, a murine anti-glycoprotein IIb/IIIa monoclonal antibody in the rat. J Pharmacol Exp Ther 298:165-171.
46. Hansen RJ, Balthasar JP. 2002. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 100:2087-2093.
47. Hansen RJ, Balthasar JP. 2002. Intavenous immunoglobulin mediates an increase in antiplatelet antibody clearance via the FcRn receptor. Thrombosis Haemostasis 88:898-899.
48. Hansen RJ, Balthasar JP. 2003. PK/PD modeling of the effects of intravenous immunoglobulin on the disposition of anti-platelet antibodies in a rat model of immune thrombocytopenia. J Pharmaceut Sci 92:1206-1215.
49. Ghetie V, Ward ES. 1997. FcRn: The MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18:592-598.
50. Haymann JP, Levraud JP, Bouet S, Kappes V, Hagege J, Nguyen G, Xu Y, Rondeau E, Sraer JD. 2000. Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol 11:632-639.
51. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, et al. 1989. Designing CD4 immunoadhesins for AIDS therapy. Nature 337: 525-531.
52. da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS. 2002. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/ CD16-dependent apoptosis of CD2(+) cells. J Immunol 168:4462-4471.
53. Goodman GE, Beaumier P, Hellstrom I, Fernyhough B, Hellstrom KE. 1985. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 3:340-3452.
54. Ober RJ, Radu CG, Ghetie V, Ward ES. 2001. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies. Int Immunol 13:1551-1559.
55. Meijer RT, Koopmans RP, ten Berge IJ, Schellekens PT. 2002. Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. J Pharmacol Exp Ther 300:346-353.
56. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. 1999. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26:78-83.
57. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. 1999. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397-420.
58. Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR. 2003. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 307:969-976.
59. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. 1994. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1:365-372.
60. 2 domains. Mol Immunol 29:213-220.
61. Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, Jones WE, Frazier D, Miatkowski K, Hochman PS. 1995. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: Cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 2:159-171.
62. Newkirk MM, Novick J, Stevenson MM, Fournier MJ, Apostolakos P. 1996. Differential clearance of glycoforms of IgG in normal and autoimmuneprone mice. Clin Exp Immunol 106:259-264.
63. Gillies SD, Lo KM, Burger C, Lan Y, Dahl T, Wong WK. 2002. Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin Cancer Res 8:210-216.
64. Pendley C, Schantz A, Wagner C. 2003. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5:172-179.
65. Schellekens H. 2002. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24:1720-1740, discussion 1719.
66. Patten PA, Schellekens H. 2003. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev Biol (Basel) 112:81-97.
67. Harlow E, Lane D. 1988. Antibodies. A laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory, 114p.
68. Gobburu JV, Tenhoor C, Rogge MC, Frazier DE, Jr., Thomas D, Benjamin C, Hess DM, Jusko WJ. 1998. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. J Pharmacol Exp Ther 286:925-930.
69. Rehlaender BN, Cho MJ. 1998. Antibodies as carrier proteins. Pharm Res 15:1652-1656.
70. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB, Jr., Adelman DC. 1997. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100:110-121.
71. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. 1991. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351-1359.
72. Grene-Lerouge NA, Bazin-Redureau MI, Debray M, Scherrmann JM, 1996. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol Appl Pharmacol 138:84-89.
73. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. 1995. Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55:4611-4622.
74. Richter WF, Gallati H, Schiller CD. 1999. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos 27:21-25.
75. Bazin-Redureau M, Pepin S, Hong G, Debray M, Scherrmann JM. 1998. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab′)2. Toxicol Appl Pharmacol 150: 295-300.
76. Sullivan JB, Jr. 1987. Past, present, and future immunotherapy of snake venom poisoning. Ann Emerg Med 16:938-944.
77. Berkowitz B, Spector S. 1972. Evidence for active immunity to morphine in mice. Science 178: 1290-1292.
78. Pentel PR, Keyler DE. 1995. Drug-specific antibodies as antidotes for tricyclic antidepressant overdose. Toxicol Lett 82-83:801-806.
79. Antman EM, Wenger TL, Butler VP, Jr., Haber E, Smith TW. 1990. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 81:1744-1752.
80. Putterman C, Ben-Chetrit E, Caraco Y, Levy M. 1991. Colchicine intoxication: Clinical pharmacology, risk factors, features, and management. Semin Arthritis Rheum 21:143-155.
81. Teng NN, Kaplan HS, Hebert JM, Moore C, Douglas H, Wunderlich A, Braude AI. 1985. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790-1794.
82. Davis CB, Tobia LP, Kwok DC, Oishi CM, Kheterpal N, Hepburn TW, Benincosa LJ, Chow F, Jusko WJ. 1999. Accumulation of antibody-target complexes and the pharmacodynamics of clotting after single intravenous administration of humanized anti-factor IX monoclonal antibody to rats. Drug Delivery 6:171-179.
83. Benincosa LJ, Chow FS, Tobia LP, Kwok DC, Davis CB, Jusko WJ. 2000. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J Pharmacol Exp Ther 292:810-816.
84. Balsari A, Menard S, Colnaghi MI, Ghione M. 1991. Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin. Int J Cancer 47:889-892.
85. Balthasar J, Fung HL. 1994. Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: Studies using digoxin as a model drug. J Pharmacol Exp Ther 268:734-739.
86. Lobo ED, Soda DM, Balthasar JP. 2003. Application of pharmacokinetic- pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice. J Pharmaceut Sci 92:1665-1676.
87. Scherrmann JM, Terrien N, Urtizberea M, Pierson P, Denis H, Bourre JM. 1989. Immunotoxicotherapy: Present status and future trends. J Toxicol Clin Toxicol 27:1-35.
88. Sabouraud AE, Urtizberea M, Cano NJ, Grandgeorge M, Rouzioux JM, Scherrmann JM. 1992. Colchicine-specific Fab fragments alter colchicine disposition in rabbits. J Pharmacol Exp Ther 260:1214-1219.
89. Valentine JL, Owens SM. 1996. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther 278:717-724.
90. Ujhelyi MR, Robert S. 1995. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 28:483-493.
91. Sabouraud AE, Urtizberea M, Benmoussa K, Cano NJ, Scherrmann JM. 1992. Fab-bound colchicine appears to adopt Fab fragment disposition in rats. J Pharm Pharmacol 44:1015-1019.
92. Allen NM, Dunham GD, Sailstad JM, Findlay JW. 1991. Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment. Dicp 25:1315-1320.
93. Ujhelyi MR, Robert S, Cummings DM, Colucci RD, Sailstad JM, Vlasses PH, Findlay JW, Zarowitz BJ. 1993. Disposition of digoxin immune Fab in patients with kidney failure. Clin Pharmacol Ther 54:388-394.
94. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, Bair HJ, Wolf FG, Becker WS, Goldenberg DM. 1995. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 55:3825-3834.
95. Behr TM, Becker WS, Sharkey RM, Juweid ME, Dunn RM, Bair HJ, Wolf FG, Goldenberg DM. 1996. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 37:829-833.
96. Balthasar JP, Fung HL. 1996. Inverse targeting of peritoneal tumors: Selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. J Pharm Sci 85:1035-1043.
97. Keyler DE, Le Couteur DG, Pond SM, St Peter JV, Pentel PR. 1995. Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver. J Pharmacol Exp Ther 272:1117-1123.
98. Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM. 2003. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol 461:119-128.
99. May LT, Neta R, Moldawer LL, Kenney JS, Patel K, Sehgal PB. 1993. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J Immunol 151:3225-3236.
100. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR. 1993. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti- cytokine antibody complexes. J Immunol 151:1235-1244.
101. Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Maliszewski CR. 1993. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 150:2717-2723.
102. Faulstich H, Kirchner K, Derenzini M. 1988. Strongly enhanced toxicity of the mushroom toxin alpha-amanitin by an amatoxin-specific Fab or monoclonal antibody. Toxicon 26:491-499.
103. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697-1702.
104. Lobo ED, Balthasar JP. 2003. Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. J Pharmaceut Sci 92: 1654-1664.
105. Racine-Poon A, Botta L, Chang TW, Davis FM, Gygax D, Liou RS, Rohane P, Staehelin T, van Steijn AM, Frank W. 1997. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther 62:675-690.
106. Chow FS, Benincosa LJ, Sheth SB, Wilson D, Davis CB, Minthorn EA, Jusko WJ. 2002. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther 71:235-245.
107. Emmons C, Hunsicker LG. 1987. Muromonab-CD3 (Orthoclone OKT3): The first monoclonal antibody approved for therapeutic use. Iowa Med 77:78-82.
108. Prodinger WM, Wurzner R, Erdei A, Dierich MP. 1999. Complement. In: Fundamental immunology, 4th edn. Philadelphia: Lippincott-Raven, pp 967-995.
109. Gessner JE, Heiken H, Tamm A, Schmidt RE. 1998. The IgG Fc receptor family. Ann Hematol 76:231-248.
110. Stevenson GT, Anderson VA, Leong WS. 2002. Engineered antibody for treating lymphoma. Recent Results Cancer Res 159:104-112.
111. Presta LG, Shields RL, Namenuk AK, Hong K, Meng YG. 2002. Engineering therapeutic antibodies for improved function. Biochem Soc Trans 30:487-490.
112. Sharma A, Davis CB, Tobia LA, Kwok DC, Tucci MG, Gore ER, Herzyk DJ, Hart TK. 2000. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther 293:33-41.
113. Dayneka NL, Garg V, Jusko WJ. 1993. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharmaceut 21: 457-478.
114. Chapman TM, Keating GM. 2003. Basiliximab: A review of its use as induction therapy in renal transplantation. Drugs 63:2803-2835.
115. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. 1998. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338:161-165.
116. Kovarik JM, Kahan BD, Rajagopalan PR, Bennett W, Mulloy LL, Gerbeau C, Hall ML. 1999. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation 68:1288-1294.
117. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
118. Trail PA, Bianchi AB. 1999. Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol 11:584-588.
119. Heath TD, Montgomery JA, Piper JR, Papahadjopoulos D. 1983. Antibody-targeted liposomes: Increase in specific toxicity of methotrexate-gamma-aspartate. Proc Natl Acad Sci USA 80: 1377-1381.
120. Bragman KS, Heath TD, Papahadjopoulos D. 1983. Simultaneous interaction of monoclonal antibody-targeted liposomes with two receptors on K562 cells. Biochim Biophys Acta 730:187-195.
121. Springer CJ, Bagshawe KD, Sharma SK, Searle F, Boden JA, Antoniw P, Burke PJ, Rogers GT, Sherwood RF, Melton RG. 1991. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer 27:1361-1366.
122. Bagshawe KD. 1993. Antibody-directed enzyme prodrug therapy (ADEPT). [Review]. Adv Pharmacol 24:99-121.
123. Jain RK. 1987. Transport of molecules in the tumor interstitium: A review. Cancer Res 47:3039-3051.
124. Jain RK. 1990. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. [Review]. Cancer Res 50:814s-819s.
125. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, Weinstein JN. 1992. Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier. Cancer Res 52:5144-5153.
126. Baxter LT, Jain RK. 1991. Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution. Microvasc Res 41:252-272.
127. US Food and Drug Administration. 2002. First radiopharmaceutical for non-Hodgkin's lymphoma. FDA Consumer Magazine 36:3. http://www.fda. gov/fdac/departs/2002/302_upd.html#lymphoma
128. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ. 1999. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803.
129. Miller JL. 2000. FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia. Am J Health Syst Pharm 57:1202-1204.
130. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R. 2001. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490-1496.
131. Juweid ME. 2002. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice. J Nucl Med 43:1507-1529.
132. Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC, Wormann B, Brittinger G, Becker W. 2002. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 94: 1363-1372.
133. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. 2001. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41:1206-1214.
134. Mager DE, Jusko WJ. 2001. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532.
135. Zhu H, Baxter LT, Jain RK. 1997. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med 38:731-741.
136. Halin C, Zardi L, Neri D. 2001. Antibody-based targeting of angiogenesis. News Physiol Sci 16: 191-194.
137. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. 1995. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 26:1665-1671.
138. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. 2003. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clin Ther 25:1700-1721.
139. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH, Mackinnon S, Hale G. 2003. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 102:404-406.
140. Kovarik JM, Nashan B, Neuhaus P, Clavien PA, Gerbeau C, Hall ML, Korn A. 2001. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther 69:201-209.
141. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. 2003. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348-365.
142. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. 2003. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med 44:465-474.
143. Cornillie F, Shealy D, G DH, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P. 2001. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 15:463-473.
144. Hooks MA, Wade CS, Millikan WJ, Jr. 1991. Muromonab CD-3: A review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11:26-37.
145. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Jr., Carlin D, Connor E. 1998. Safety, tolerance, and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 17:110-115.
146. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195.
147. Tokuda Y, Watanabe T, Omuro Y, Ando M, Katsumata N, Okumura A, Ohta M, Fujii H, Sasaki Y, Niwa T, Tajima T. 1999. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 81:1419-1425.